Results 161 to 170 of about 78,014 (255)

An ETH‐LAD trip with unfavourable consequences: A case report

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated. This report presents the first case with an analytically confirmed ingestion of ETH‐LAD (6‐ethyl‐6‐nor‐lysergic acid diethylamide), the N‐ethyl derivative of LSD.
Johannes Nadler   +6 more
wiley   +1 more source

Pharmacokinetic Assessment of Atazanavir and Favipiravir Following Echinacea Supplementation: A Controlled Herb–Drug Interaction Investigation

open access: yesBiopharmaceutics &Drug Disposition, EarlyView.
Pharmacokinetic interactions between Echinacea and two antiviral drugs, favipiravir and atazanavir, were assessed in rats. The findings suggest that Echinacea does not significantly affect the pharmacokinetics of favipiravir and atazanavir. These results provide preliminary evidence that concurrent use of Echinacea with these antiviral drugs may be ...
Siva Nageswara Rao Gajula   +4 more
wiley   +1 more source

Glycoengineered Recombinant Alpha1‐Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma‐Derived Protein

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Alpha‐1‐antitrypsin (A1AT) is a multifunctional, clinically important, high‐value therapeutic glycoprotein that can be used for the treatment of many diseases, such as A1AT deficiency, diabetes, graft‐versus‐host disease, cystic fibrosis, and various viral infections. Currently, the only U.S. food and drug administration‐approved treatment for
Frances Rocamora   +12 more
wiley   +1 more source

Artificial Cell Catalysts for Biotransformation: Design Principles and Process Integration

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Artificial cell catalysts are emerging as programmable biocatalytic platforms for sustainable molecular conversion. By reconstituting enzymes and functional modules within synthetic compartments, they combine the selectivity of biological catalysis with the design flexibility of synthetic materials.
Iori Kobayashi   +2 more
wiley   +1 more source

Regenerative perfusion bioreactor for biologics production with lower COGs

open access: yesBiotechnology Progress, EarlyView.
Abstract Perfusion bioreactor systems enable intensified bioprocessing with high cell densities and volumetric productivities in monoclonal antibody (mAb) manufacturing. However, their widespread adoption remains constrained by the high consumption of chemically defined cell culture media.
Eric Wynne   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy